For colorectal cancer treatment in the pre-, early-, and late-tumor phase, 17 EGFR-specific peptides were selected by phage display: QRHKPRE, HAHRSWS, YLTMPTP, TYPISFM, KLPGWSG, IQSPHFF, YSIPKSS, SHRNRPRNTQPS, NRHKPREKTFTD, TAVPLKRSSVTI, GHTANRQPWPND, LSLTRTRHRNTR, RHRDTQNHRPTN, ARHRPKLPYTHT, KRPRTRNKDERR, SPMPQLSTLLTR, and NHVHRMH (Patent WO 2016/029125 A1—Peptide reagents and methods for detection and targeting of dysplasia, early cancer, and cancer). This evidence concerns the gene EGFR and cancer.